New Study Confirms Tresiba (insulin degludec) U200 Delivers Significantly Lower Rates of Confirmed Hypoglycaemia Versus Insulin Glargine U100. New data presented at the 51st annual meeting of the European Association for the Study of Diabetes (EASD) show that patients with type 2 diabetes receiving the U200 formulation of Tresiba (insulin degludec) experienced significantly lower rates of confirmed hypoglycaemia and significantly reduced mean fasting blood glucose compared to those receiving insulin glargine U100. Degludec U200 is twice as concentrated as U100, allowing patients to inject up to 160 units in a single injection, rather than in two separate injections.
He more concentrated formulation of Tresiba also means fewer injections, which will be a welcome option for those patients who require higher than 80 units. The 32-week, open-label, crossover, treat-to-target trial…
